Tripos, Pharsight, Wageningen University and Research Centre, DNAStar, Whitehead Institute, Proteomics and Mass Spectrometry Facility-University of Massachusetts Medical School, Harvard Medical School, SGI, University of South Carolina | GenomeWeb
Tripos to Acquire Pharsight for $57M
 
Tripos said this week that it will acquire clinical software and regulatory services firm Pharsight for approximately $57 million in cash.
 
Tripos, owned by private equity firm Vector Capital, will pay $5.50 for each outstanding share of common stock of publicly traded Pharsight. The price represents a 29 percent premium over the average closing price of Pharsight’s stock for the 30-day trading period ended Sept. 8, the day before the acquisition was announced.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.